Early Assets Excite At Novartis R&D Day
430 drug discovery projects trimmed to 325
NIBR chief Jay Bradner tells Scrip that the Swiss major's focus is on developing first in class therapies rather than 'fast-follower' research seen across the biopharma sector.
